An in vivo - in vitro study of cefepime and cefazolin dialytic clearance during high-flux hemodialysis

Pharmacotherapy

Volumn 28, Issue 8, 2008, Pages 977-983

  Maynor, Lena M ^a   Carl, Daniel E ^b   Matzke, Gary R ^b   Gehr, Todd W B ^b   Farthing, Christine ^b   Farthing, Don ^b   Brophy, Donald F ^b  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Cefazolin; Cefepime; Dialytic clearance; Hemodialysis; In vitro; In vivo

Indexed keywords

BUFFERED SIMULATED PLASMA WATER; CEFAZOLIN; CEFEPIME; POLYSULFONE; WATER;

ADULT; ARTICLE; ARTIFICIAL KIDNEY; BLOOD FLOW VELOCITY; CLINICAL ARTICLE; CORRELATION ANALYSIS; DIALYSIS MEMBRANE; DRUG CLEARANCE; DRUG PROTEIN BINDING; FEMALE; FLOW RATE; HEMODIALYSIS; HUMAN; MALE; OPEN STUDY; PLASMA; PROSPECTIVE STUDY; SIMULATION; SINGLE DRUG DOSE; UNITED STATES; UNIVERSITY HOSPITAL;

ADULT; ANTI-BACTERIAL AGENTS; CEFAZOLIN; CEPHALOSPORINS; FEMALE; HEMOLYSIS; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 48249121546     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.8.977     Document Type: Article

References (26)

1. Stryjewski ME, Szczech LA, Benjamin DK, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus infections. Clin Infect Dis 2007;44:190-6.
2. Bristol-Myers Squibb. Maxipime (cefepime) package insert. Princeton, NJ; 2003.
3. Gilbert DN, Moellering RC, Eliopoulos GM, Sande MA, eds. The Sanford guide to antimicrobial therapy, 37th ed. Sperryville, VA: Antimicrobial Therapy, Inc., 2007:170.
4. GlaxoSmithKline. Ancef (cefazolin) package insert. Research Triangle Park, NC; 2005.
5. Matzke GM, Comstock TJ. Influence of renal function and dialysis on drug disposition. In: Burton ME, Shaw LM, Schentag JJ, Evans WE, eds. Applied pharmacokinetics and pharmacodynamics. Principles of therapeutic drug monitoring, 4th ed. Philadelphia: Lippincott, Williams & Wilkins, 2006:188-212.
6. Hemodialysis Adequacy 2006 Working Group. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 2006;48(suppl 1):S2-90.
7. Marx MA, Frye FR, Matzke GR, Golper TA. Cefazolin as empiric therapy in hemodialysis-related infections: efficacy and blood concentrations. Am J Kidney Dis 1998;32:410-14.
8. Wong KM, Chan WK, Chan YH, Li CS. Cefepime-related neurotoxicity in a hemodialysis patient [letter]. Nephrol Dial Transplant 1999;14:2265-6.
9. Lam S, Gomolin IH. Cefepime neurotoxicity: case report, pharmacokinetic considerations, and literature review. Pharmacotherapy 2006;26:1169-74.
10. Dixit S, Kurle P, Buyan-Dent L, Sheth RD. Status epilepticus associated with cefepime. Neurology 2000;54:2153-5.
11. Ferrara N, Abete P, Giordano M, et al. Neurotoxicity induced by cefepime in a very old hemodialysis patient. Clin Nephrol 2003;59:388-90.
12. Barbey F, Bugnon D, Wauters JP. Severe neurotoxicity of cefepime in uremic patients [letter]. Ann Intern Med 2001;135:1011.
13. Fishbain JT, Monahan TP, Canonico MM. Cerebral manifestations of cefepime toxicity in a dialysis patient. Neurology 2000;55:1756-7.
14. Alpay H, Altun Ö, Çiyikh NK. Cefepime-induced non-convulsive status epilepticus in a peritoneal dialysis patient. Pediatr Nephrol 2004;19:445-7.
15. Arkaravichien W, Tamungklang J, Arkaravichien T. Cefazolin induced seizures in hemodialysis patients. J Med Assoc Thai 2006;89:1981-3.
16. Hudson JQ, Comstock TJ. Evaluation of an in vitro dialysis system to predict drug removal. Nephrol Dial Transplant 2004;19:400-5.
17. Farthing C, Farthing D, Brophy DF, et al. High-performance liquid chromatographic determination of cefepime and cefazolin in human plasma and dialysate. Chromatographia 2008;67:365-8.
18. Sowinski KM, Mueller BA, Grabe DW, et al. Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers. Am J Kidney Dis 2001;37:766-76.
19. Barbhaiya RH, Knupp CA, Forgue ST, Matzke GR, Guay DR, Pittman KA. Pharmacokinetics of cefepime in subjects with renal insufficiency. Clin Pharmacol Ther 1990;48:268-76.
20. Craig WA, Welling PG, Jackson TC, Kunin CM. Pharmacology of cefazolin and other cephalosporins in patients with renal insufficiency. J Infect Dis 1973;128:S347-50.
21. Greene DS, Tice AD. Effect of hemodialysis on cefazolin protein binding. J Pharm Sci 1977;66:1508-10.
22. Barbhaiya RH, Forgue ST, Gleason CR, et al. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob Agents Chemother 1992;36:552-7.
23. Schmaldienst S, Traunmüller F, Burgmann H, et al. Multiple-dose pharmacokinetics of cefepime in long-term hemodialysis with high-flux membranes. Eur J Clin Pharmacol 2000;56:61-4.
24. Woods HF, Nandakumar M. Improved outcome for hemodialysis patients treated with high-flux membranes. Nephrol Dial Transplant 2000:15:S36-42.
25. Fogel MA, Nussbaum PB, Feintzeig ID, Hunt WA, Gavin JP, Kim RC. Cefazolin in chronic hemodialysis patients: a safe, effective alternative to vancomycin. Am J Kidney Dis 1998;32:410-19.
26. Rowland M, Towzer TN, eds. Dialysis. In: Clinical pharmacokinetics: concepts and applications, 3rd ed. Baltimore: Lippincott, Williams & Wilkins, 1995:443-62.